High Prevalence and Undertreatment of Hypercholesterolaemia in Participants in a Public Stroke Prevention Programme in Austria

Overview

Journal Clin Drug Investig

Date 2007 May 30

PMID 17532717

Citations 3

Authors

Bernhard Iglseder

Titus Moroder

Wolfgang Staffen

Gunther Ladurner

Affiliations

Soon will be listed here.

Abstract

Background: There is remarkable consistency in large cohort studies regarding the relationship between serum cholesterol and the incidence of coronary heart disease (CHD), and increasing interest in the relationship between serum cholesterol and stroke. The aim of our investigation was to identify the prevalence and control of hypercholesterolaemia in participants in a public stroke prevention programme.

Patients And Methods: 9274 participants were categorised according to the guidelines of the National Cholesterol Education Program-Adult Treatment Panel III (NCEP-ATP III) and analysed with reference to risk category, treatment eligibility and treatment quality.

Results: NCEP-ATP III identifies low-density lipoprotein (LDL) cholesterol as the primary target of treatment. In this programme, 499 (5.4%) subjects were classified as having optimal (<100 mg/dL) LDL cholesterol levels, 1718 (18.5%) as near optimal (100-129 mg/dL), 2863 (30.9%) as borderline high (130-159 mg/dL), 2472 (26.7%) as high (160-189 mg/dL) and 1722 (18.6%) as very high (>190 mg/dL). 4442 (47.9%) participants presented with 0-1 risk factors, 2451(26.4%) with multiple (2+) risk factors, and 2381 (25.7%) met the criteria of secondary prevention. The suggested treatment goals were met in 2411 (54.3%) participants with 0-1 risk factors, in 561 (22.9%) of the multiple-risk-factor group, and in 148 (6.2%) subjects with established CHD or risk equivalents. A total of 871 subjects (9.4%) reported use of cholesterol-lowering drugs.

Conclusions: We observed a considerable prevalence and poor control of hypercholesterolaemia in participants in a public stroke prevention programme in Austria.

Citing Articles

Lipid lowering therapy in primary and secondary prevention in Austria: are LDL-C goals achieved? : Results from the DA VINCI study.

Siostrzonek P, Brath H, Zweiker R, Drexel H, Hoelzl R, Hemetsberger M Wien Klin Wochenschr. 2021; 134(7-8):294-301.

PMID: 34870742 PMC: 9023395. DOI: 10.1007/s00508-021-01978-w.

Unmet need in the hyperlipidaemia population with high risk of cardiovascular disease: a targeted literature review of observational studies.

Mitchell S, Roso S, Samuel M, Pladevall-Vila M BMC Cardiovasc Disord. 2016; 16:74.

PMID: 27114245 PMC: 4845323. DOI: 10.1186/s12872-016-0241-3.

CEPHEUS SA: a South African survey on the undertreatment of hypercholesterolaemia.

Raal F, Schamroth C, Blom D, Marx J, Rajput M, Haus M Cardiovasc J Afr. 2011; 22(5):234-40.

PMID: 21922121 PMC: 3721857. DOI: 10.5830/CVJA-2011-044.

References

Shepherd J, Cobbe S, Ford I, Isles C, LORIMER A, Macfarlane P . Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995; 333(20):1301-7. DOI: 10.1056/NEJM199511163332001. View

Whincup P, Emberson J, Lennon L, Walker M, Papacosta O, Thomson A . Low prevalence of lipid lowering drug use in older men with established coronary heart disease. Heart. 2002; 88(1):25-9. PMC: 1767195. DOI: 10.1136/heart.88.1.25. View

Wolf P, DAgostino R, Belanger A, Kannel W . Probability of stroke: a risk profile from the Framingham Study. Stroke. 1991; 22(3):312-8. DOI: 10.1161/01.str.22.3.312. View

Di Napoli P, Taccardi A, Oliver M, De Caterina R . Statins and stroke: evidence for cholesterol-independent effects. Eur Heart J. 2002; 23(24):1908-21. DOI: 10.1053/euhj.2002.3236. View

. Cholesterol, diastolic blood pressure, and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts. Prospective studies collaboration. Lancet. 1995; 346(8991-8992):1647-53. View

Monkman D . Treating dyslipidaemia in primary care. The gap between policy and reality is large in the UK. BMJ. 2000; 321(7272):1299-300. PMC: 1119049. DOI: 10.1136/bmj.321.7272.1299. View

Chambless L, Folsom A, Clegg L, Sharrett A, Shahar E, Nieto F . Carotid wall thickness is predictive of incident clinical stroke: the Atherosclerosis Risk in Communities (ARIC) study. Am J Epidemiol. 2000; 151(5):478-87. DOI: 10.1093/oxfordjournals.aje.a010233. View

Brunner E, Cohen D, Toon L . Cost effectiveness of cardiovascular disease prevention strategies: a perspective on EU food based dietary guidelines. Public Health Nutr. 2001; 4(2B):711-5. DOI: 10.1079/phn2001161. View

Mosca L, Jones W, King K, Ouyang P, Redberg R, Hill M . Awareness, perception, and knowledge of heart disease risk and prevention among women in the United States. American Heart Association Women's Heart Disease and Stroke Campaign Task Force. Arch Fam Med. 2000; 9(6):506-15. DOI: 10.1001/archfami.9.6.506. View

10.

Law M, Wald N, Thompson S . By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease?. BMJ. 1994; 308(6925):367-72. PMC: 2539460. DOI: 10.1136/bmj.308.6925.367. View

11.

OLeary D, Polak J, Kronmal R, Manolio T, Burke G, WOLFSON Jr S . Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med. 1999; 340(1):14-22. DOI: 10.1056/NEJM199901073400103. View

12.

Primatesta P, Poulter N . Lipid concentrations and the use of lipid lowering drugs: evidence from a national cross sectional survey. BMJ. 2000; 321(7272):1322-5. PMC: 27537. DOI: 10.1136/bmj.321.7272.1322. View

13.

Sever P, Dahlof B, Poulter N, Wedel H, Beevers G, Caulfield M . Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre.... Lancet. 2003; 361(9364):1149-58. DOI: 10.1016/S0140-6736(03)12948-0. View

14.

. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998; 339(19):1349-57. DOI: 10.1056/NEJM199811053391902. View

15.

Oliver M . Might treatment of hypercholesterolaemia increase non-cardiac mortality?. Lancet. 1991; 337(8756):1529-31. DOI: 10.1016/0140-6736(91)93208-q. View

16.

Iglseder B, Moroder T, Staffen W, Ladurner G . Inadequate management of cerebrovascular risk factors in participants of a public stroke prevention program in Austria. Eur J Neurol. 2004; 11(10):679-85. DOI: 10.1111/j.1468-1331.2004.00912.x. View

17.

van Hout B, Simoons M . Cost-effectiveness of HMG coenzyme reductase inhibitors; whom to treat?. Eur Heart J. 2001; 22(9):751-61. DOI: 10.1053/euhj.2000.2308. View

18.

. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001; 285(19):2486-97. DOI: 10.1001/jama.285.19.2486. View

19.

Lindenstrom E, Boysen G, Nyboe J . Influence of total cholesterol, high density lipoprotein cholesterol, and triglycerides on risk of cerebrovascular disease: the Copenhagen City Heart Study. BMJ. 1994; 309(6946):11-5. PMC: 2542648. DOI: 10.1136/bmj.309.6946.11. View

20.

. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002; 360(9326):7-22. DOI: 10.1016/S0140-6736(02)09327-3. View